Abstract
Renal dysfunction is commonly seen in patients with end stage liver disease. Prognosis of patients who develop hepatorenal syndrome (HRS) is dismal with a median survival of around six months without liver transplantation. Advances in understanding of the pathophysiology of HRS has lead to evolving ideas regarding the definition and diagnostic criteria of HRS. In addition, recent pharmacological and other therapeutic innovations provide hope to patients of HRS. This is a review of diagnostic criteria, etio-pathogenesis and therapeutic options for patients of HRS based on the available evidence in literature.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.